HCM News and Press, HUTCHMED (China) Limited From 08/09/22

Hutchmed (China) ( NASDAQ: HCM ) and Inmagene Biopharmaceuticals said the first person based in the U.S. was dosed in a global phase 1 trial of IMG-004. Inmagene is developing IMG-004 to potentially treat immunological diseases. The study aims to eva...

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in the Unite...

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHA...

Hutchmed (China) ( NASDAQ: HCM ) said its medicine fruquintinib met the main goal of overall survival (OS) in patients with advanced, refractory metastatic colorectal cancer (CRC) in a phase 3 trial. The study called FRESCO-2 evaluated fruquintinib plus be...

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan ȁ...

HUTCHMED (China) Limited (HCM) Q2 2022 Earnings Conference Call August 02, 2022 08:00 AM ET Company Participants Weiguo Su - Executive Director, Chief Executive Officer and Chief Scientific Officer Johnny Cheng - Executive Director and Chief Financial Officer Mar...

HUTCHMED (China) Limited (HCM) Q2 2022 Earnings Conference Call August 02, 2022 08:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chie...

The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2022 Q2 earnings call. For further details see: HUTCHMED (China) Limited 2022 Q2 - Results - Earnings Call Presentation

Hutchison China MediTech press release ( NASDAQ: HCM ): 1H GAAP EPADS of -$0.96. Revenue of $202.05M (+28.4% Y/Y). Oncology/Immunology consolidated revenues for FY2022 to be in the range of $160M to $190M. “We have driven revenue growth in our innovative por...

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE ® , SULANDA ® and ORPATHYS ® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO ...